Tianshu Pharmaceutical Obtains Two API Registration Numbers for the First Time

Recently, Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) received the acceptance notices for two API varieties, dapagliflozin and  vonoprazan fumarate, issued by the Center for Drug Evaluation of the National Medical Products Administration, and successfully obtained the registration numbers.

The first successful registration of the two API varieties, dapagliflozin and vonoprazan fumarate, by Tianshu Pharmaceutical is another important milestone after the enterprise successfully obtained the "Drug Production License" in December 2023. It marks that Tianshu Pharmaceutical has officially entered the API CDMO supply library field, and also represents that Tianshu Pharmaceutical's role as an important link in the "Chemistry + Pharmacy + Medicine" one-stop CRO/CDMO full-industry-chain layout built by Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare) has been strongly verified. In the future, relying on Nanjing Vcare's strong R&D and technological innovation capabilities, Tianshu Pharmaceutical will continue to enhance its pharmaceutical full-industry-chain service capabilities.

　　▲ API业务联系：姚经理 13327727315